Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Moderna Shares Are Surging After Merck Exercised Personalized Cancer Vaccine Pact

Published 12/10/2022, 14:26
Updated 12/10/2022, 15:40
© Reuters.  Moderna Shares Are Surging After Merck Exercised Personalized Cancer Vaccine Pact
MRK
-
MRCG
-
MKKGY
-
MRCK34
-
M1RN34
-

  • Moderna Inc (NASDAQ: NASDAQ:MRNA) said Merck & Co Inc (NYSE: MRK) had exercised an option to jointly develop and potentially sell personalized mRNA-based cancer vaccine.
  • Personalized cancer vaccines prime the immune system so patients can generate a tailored antitumor response to their tumor mutation signature to treat their cancer.
  • mRNA-4157/V940 is designed to stimulate an immune response by generating T-cell responses based on the mutational signature of a patient's tumor.
  • Also Read: Moderna Says No To China's Request To Handover COVID-19 Vaccine Technology.
  • In a Phase 2 trial, the vaccine mRNA-4157 is being tested along with Merck's blockbuster cancer immunotherapy Keytruda as adjuvant treatment for patients with high-risk melanoma conducted by Moderna.
  • Data on the vaccine is expected in the fourth quarter of this year.
  • Under the agreement, initially established in 2016 and amended in 2018, Merck will pay Moderna $250 million to exercise its option for personalized cancer vaccines. Merck and Moderna will share costs and profits equally under this worldwide collaboration.
  • Price Action: MRNA shares are up 12.30% at $135.52 during the premarket session on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.